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Abstract
Background: Chemokines and their receptors play a decisive role in tumor progression and metastasis. We recently
found a new signaling mechanism in malignant glioma cells mediated by transmembrane chemokines that
we termed “inverse signaling”. According to this hypothesis, soluble (s)-CXCL16 binds to the surface-expressed
transmembrane (tm) -CXCL16, and induces signaling and different biological effects in the stimulated cells, so
that the transmembrane ligand itself acts as a receptor for its soluble counterpart. Now, we hypothesized that
“inverse signaling” via tm-CXCL16 might also take place in meningiomas, a completely different, benign tumor entity.
Methods: We used quantitative reverse-transcription polymerase chain reaction, immunocytochemistry and western
blot to detect CXCL16 and CXCR6 in human meningioma cells isolated from 28 human meningiomas. Subsequently,
we stimulated cultured human tm-CXCL16-positive, CXCR6-negative meningioma cells with recombinant s-CXCL16
and analyzed binding, signaling and biological effects using RNAi silencing to verify specificity.
Results: In fact, cultured human meningioma cells considerably express CXCL16, but substantially lack CXCR6, the only
known CXCL16 receptor. These receptor-negative cells could bind s-CXCL16, and responded to s-CXCL16 application
with activation of the intracellular kinases ERK1/2 und Akt. As a consequence, we observed increased proliferation and
rescue of apoptosis of cultured meningioma cells. Since binding and signaling were abolished by siRNA silencing, we
concluded that tm-CXCL16 specifically acts as a receptor for s-CXCL16 also in human meningioma cells.
Conclusion: These findings underline our recent report on the mechanism of inverse signaling as a broad biological
process also observable in more benign tumor cells and contributing to tumor progression.
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Plain english summary
Cells communicate by ligands that bind to their respective
receptors. Some ligands are transmembrane molecules
which means they span through the cell membrane. The
part of these ligands at the outer cell surface can be liber-
ated from its membrane stack yielding a soluble ligand
that is present outside of the cell and can meet
corresponding receptors at the surface of the same or an-
other cell. Some tumor cells have high levels of transmem-
brane ligands but do not produce the corresponding
receptors for these molecules. Serendipitously, in malig-
nant brain tumor cells we detected a novel, alternate
mechanism of cell communication which we term “in-
verse signaling”: Here, a transmembrane ligand (namely
transmembrane chemokines) acts as a “receptor” for its
soluble counterpart. By studying now benign human
tumor cells derived from the linings of the brain and
spinal cord, so called meningiomas, Hattermann et al.
show that the soluble form of the transmembrane
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chemokine CXCL16 binds to its transmembrane equiva-
lent in these tumor cells, too. This interaction initiates
intracellular signaling pathways that promote cell growth
and make the meningioma cells more resistant to cell
death. Thus, Hattermann et al. showed that the “inverse
signaling” paradigm also takes place in benign tumor cells,
suggesting that it helps to fine-tune the communication
between cells as a broad biological process.
Background
The chemokine CXCL16 (synonym SR-PSOX) was origin-
ally discovered as a scavenger receptor for oxidized LDL
[1], and independently as a ligand for the CXC-chemokine
receptor CXCR6, also termed Bonzo, TYMSTR, STRL33
[2]. CXCL16 is synthesized as a transmembrane (tm)
multi-domain molecule consisting of a chemokine domain
followed by a glycosylated mucin-like stalk, a single trans-
membrane helix and an intracellular tail. However, a
soluble (s-)CXCL16 form can be generated by constitutive
or induced cleavage from the transmembrane form by the
cell-surface proteases ADAM10 and 17 (ADAM, a disinte-
grin and metalloproteinase) [3, 4].
In previous investigations we and others determined
that CXCL16 is definitely involved in tumor progression
of different tumor types, e.g. gliomas, schwannomas,
lung and breast tumors [5–9]. However, apart from its
classical signaling mode in which the proteolytically
released chemokine domain would bind to and signal via
its receptor CXCR6, we recently discovered an alternate
signaling mechanism for transmembrane chemokines in
glioma cells which we termed “inverse signaling” [10].
According to this novel mechanism, the proteolytically
released (or also recombinant) s-chemokine binds to an
intact transmembrane chemokine specimen inducing
intracellular signaling and biological effects independently
from the expression of the receptor CXCR6. We initially
demonstrated this mechanism in cultivated malignant
human glioma cells, from which we had previously shown
to express high levels of CXCL16, but a lack of the corre-
sponding receptor CXCR6 [11].
Apart from that, we could show that solid human
meningiomas - the second most common intracranial
tumors - are also characterized by high expression levels
of CXCL16 while CXCR6 expression is more restricted
[12]. Meningiomas develop from arachnoid cap cells,
and although malignant variants exist (atypical meningi-
omas, World Health Organization, WHO grade II and
anaplastic meningiomas, WHO grade III) most meningi-
omas (about 90 %) are slowly growing benign (WHO
grade I) tumors [13, 14].
Facing the high CXCL16 expression levels in human
meningiomas, we raised the question if “inverse signal-
ing” of CXCL16 previously observed in highly malignant
glioma cell might also take place in benign meningioma
cells. Therefore, we analyzed binding, intracellular signal-
ing effects and different biological readouts in cultured
primary human meningioma cells upon stimulation with
s-CXCL16. This should validate our recent hypothesis on
inverse signaling in more benign brain tumor cells as a
broader biological process.
Methods
Tumor specimens
Meningioma samples were surgical dissected tissues
from the Department of Neurosurgery (Kiel, Germany)
and were obtained in accordance with the Helsinki Dec-
laration of 1975 with approval of the ethics committee
of the University of Kiel, Germany (file reference: D 442/
11) after written consent of donors. Tumors were classi-
fied according to the WHO criteria into the various
subtypes of meningiomas [13]. The diagnosis was estab-
lished by a pathologist. In this study, a total number of
28 meningiomas were included (P1 to P28). With excep-
tion of P10, P25, P27 and P28 all meningiomas were
classified into WHO grade one, P10, P25, P27 and P28
were grad two meningiomas. If possible (enough mater-
ial available), for different investigations matched probes
of individual tumor samples were used (see Table 1).
Real-time RT-PCR (qRT-PCR)
RNA was isolated with the TRIZOL reagent (Invitrogen,
Carlsbad, CA, USA), digested by DNase, cDNA was
synthesized, and quantitative real time RT-PCR (qRT-
PCR) was performed [12, 15] using TaqMan primer
probes (Applied Biosystems, Foster City, CA, USA):
hGAPDH (Hs99999905_m1), hCXCL16 (Hs00222859_m1),
hCXCR6 (Hs00174843_m1). All 28 different meningioma
samples were analyzed by qRT-PCR. The reaction was car-
ried out with the MyiQ™ Single Color Real-time PCR De-
tection System (BIO-RAD, München, Germany) and
fluorescent data were converted into cycle threshold (CT)
measurements. ΔCT values of each sample were calculated
as CTgene of interest – CT GAPDH. Relative gene expression
was calculated with 2(normalized CT non-stimulated – normalized
CT stimulated) = n-fold of control. A ΔCT value of 3.33 corre-
sponds to one magnitude lower gene expression compared
to GAPDH (glycerinaldehyde-3-phosphate-dehydrogen-
ase). For each gene, logarithmic linear dependence of CT-
values from the numbers of copies was verified by using
different amounts of cDNA.
Cell culture
It should be noted that all experiments were performed
with cells cultivated from surgical dissected tumors de-
scribed above. Primary human meningioma cells were
cultured in glutamine-supplemented Dulbecco’s modi-
fied Eagle’s medium (DMEM) plus 20 % fetal calf serum
(FCS) as described previously [15]. Subcultures from 2
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to 4 were used. Meningiomas express both mesenchymal
and epithelial markers of which EMA (epithelial mem-
brane antigen) and fibronectin can be detected in 90 to
100 % of all investigated solid meningiomas, depending
on marker and investigated cohort [16–18]. Thus, iden-
tity and purity of meningioma cell cultures were proven
routinely by fibronectin (1:100; rabbit polyclonal anti-
human fibronectin; Santa Cruz Biotechnology, Santa
Cruz, CA), EMA (1:20; mouse monoclonal anti-human
EMA; DAKO, Glostrup, Denmark), and glial fibrillary
acidic protein (GFAP) (1:200; mouse monoclonal anti-
human GFAP, DAKO) immunocytochemistry staining.
The primary antibody was omitted for negative controls.
All cultured meningiomas showed a positive staining for
EMA and fibronectin, but lack GFAP expression.
Immunocytochemistry (ICC)
For immunocytochemistry examination, cultured pri-
mary human meningioma cells were seeded on sterile
glass cover slides (50,000 cells/well for routine and
CXCL16 staining, 16,000, 64,000 and 160,000/well to in-
vestigate the density dependent expression of CXCR6)
and grown for two (for density dependent expression
analysis) to up to four days in 20 % FCS-supplemented
DMEM. In case of stimulations, cells were seeded on
glass cover slides (64,000/well), grown for two days and
stimulated for 24 h with 10 nM CXCL16 (PeproTech,
Hamburg, Germany). Then, cell were washed with phos-
phate buffered saline (PBS) for three times and fixed
with methanol-acetone (1:1; ice-cold) for 10 min and
4 % para-formaldehyde in PBS for 30 min. Non-specific
binding was blocked with 0.5 % bovine serum albumin
(BSA)/0.5 % glycine in PBS for 60 min. Glass cover slides
were incubated with anti-CXCL16 or anti-CXCR6 pri-
mary antibody over night at 4 °C (anti-CXCL16, goat
polyclonal, 1:100 and anti-CXCR6, mouse monoclonal,
1:100, both R&D Systems, Wiesbaden, Germany). The
primary antibody was omitted for negative controls.
After washing steps with PBS, glass cover slides were in-
cubated with the Alexa Fluor 555-coupled secondary
antibody (red, 1:1,500, donkey anti-goat or anti-mouse
IgG, Invitrogen, Life Technologies, Karlsruhe, Germany)
for 1 h at 37 °C in darkness. After washing with PBS, nu-
clei were stained with 4′,6-diamidino-2-phenylindole
(DAPI; Molecular Probes/Invitrogen; 1:30,000, 30 min
room temperature), washed with PBS (3×) and finally
distilled water. After embedding in Immu-Mount
(Shandon, Pittsburgh, PA, USA) digital photography was
performed using a Zeiss fluorescence microscope and
Zeiss camera (Zeiss, Jena, Germany). As a positive control
for CXCR6 immunoreactivity, we used LOX melanoma
cells transfected with an expression vector for CXCR6
(OriGene, Rockville, MD). Native LOX melanoma cells
were a kind gift of Professor Udo Schumacher, University
Hospital Hamburg-Eppendorf.
Binding experiments
Cultured primary human meningioma cells were grown
for up to four days on sterile glass cover slides in 20 %
FCS-supplemented DMEM, washed with PBS for three
times and incubated for 15 min on ice. Meningioma
cells were incubated with Cy3-labeled CXCL16 (2 μl
diluted in 50 μl PBS) or Cy3-labeled lactalbumin (2 μl
diluted in 50 μl PBS) for 60 min on ice. For labeling of
CXCL16 and lactalbumin, 2 μg protein were incubated
with a 4-fold excess of monoreactive Cy3-NHS ester (GE
Table 1 Documentation of patients’ samples and use for
experiments
Sample WHO
grade
Expression
analysis
qRT-PCR/
ICC/WB
Kinase-WB Binding Proliferation Apoptosis
P1 I X X X
P2 I X X
P3 I X X
P4 I X X X
P5 I X
P6 I X X X
P7 I X X
P8 I X X X
P9 I X X
P10 II X X
P11 I X X
P12 I X X
P13 I X X
P14 I X X
P15 I X X
P16 I X X
P17 I X
P18 I X
P19 I X
P20 I X
P21 I X
P22 I X
P23 I X
P24 I X
P25 II X
P26 I X
P27 II X
P28 II X
We included 24 WHO grade I and 4 WHO grade II tumor samples and used
cultured meningioma cells from these samples for experiments as indicated
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Healthcare, Freiburg, Germany) in 0.2 M NaHCO3
buffer, pH 8.4 (total reaction volume 90 μl). After a
washing step with PBS, cells were fixed in methanol-
acetone (1:1; ice-cold) for 10 min, and washed for
three times with PBS. Nuclei were stained with DAPI
(see above), and after embedding in Immu-Mount
(Shandon) digital photography was performed using a
Zeiss fluorescence microscope and Zeiss camera
(Zeiss).
Western blot
Primary human meningioma cells (1.5 × 105) were grown
for two days in 20 % FCS-supplemented DMEM, washed
in DMEM with 0.5 % FCS for three times (20 min, re-
spectively) and stimulated for 10 min, 20 min and
40 min in the same medium with 10 nM CXCL16
(PeproTech) or for 10 min with epidermal growth factor
(EGF; 10 ng/ml; Pepro Tech) or for 20 min with anti-
CXCL16 (1 μg/ml; R&D Systems), respectively. In paral-
lel, control cells were kept without stimulation, these
were also used to confirm lack of CXCR6 expression on
protein level by western blot [6]. Cells were harvested
with 1 ml lysis buffer [50 mM TRIS, 100 mM NaCl,
2 mM EDTA, 1 % Triton-X-100, and 1 mM sodium van-
adate, 1× Halt™ Phosphatase Inhibitor Cocktail (Thermo
Scientific, Bonn, Germany)], 3 μg of protein per sample
was loaded on 10 % SDS-polyacrylamide gels for elec-
trophoresis and then transferred to a polyvinylidene
difluoride membrane (Hybond™-P PVDF membrane,
GE Healthcare, Freiburg, Germany). As a positive control
for CXCR6, 50 ng/lane recombinant human CXCR6 (Bio-
zol, Eching, Germany) was applied in a separate lane. To
verify CXCL16 expression in membrane isolates, and to
exclude that CXCL16 stimulation might induce CXCR6
expression, meningioma cells were grown until con-
fluency, stimulated with 10 nM CXCL16 or not, and cells
were harvested and lysed in 5 mH Hepes, pH 7.4. Then,
10 vol.% 200 mM Hepes, 1.4 mM NaCl pH 7.4 was added
to each sample, detritus was removed by centrifugation
(8 min, 800 xg), and membranes were isolated by centrifu-
gation for 60 min at 14 000 xg. Membrane preparations
were solubilized in 20 mM Hepes, 0.14 mM NaCl, pH 7.4,
and protein amounts of 5 μg/lane were applied to
electrophoresis and blotting as described above. The
polyvinylidene difluoride membranes were blocked with
5 % BSA/TBST and incubated with primary antibodies
against phospho-p42/44 MAPK (Cell Signaling, Beverly,
MA, 1:1,000), phospho-Akt (Cell Signaling, 1:250),
CXCR6 (Acris, Hiddenhausen, Germany, 1:250) or
CXCL16 (PeproTech, 1:250) at 4 °C overnight. The mem-
branes were incubated with the secondary antibody
(1:30,000, donkey anti-rabbit IgG-HRP, Santa Cruz Bio-
technology) for 1 h at room temperature, and horseradish
peroxidase activity was detected by applying an ECL
Advance Western Blotting Detection Kit (GE Healthcare)
followed by exposure of the membranes to a sheet of auto-
radiography film (Hyperfilm™ECL™, GE Healthcare). Equal
protein loading was confirmed by either reprobing the
membranes with anti-ERK-2 (1:200, Santa Cruz Biotech-
nology), anti-Akt (1:500, Cell Signaling) or anti-Caveolin-1
(1:200, Santa Cruz Biotechnology) after antibody stripping
for 30 min using Reblot Stripping Solution (Millipore, Te-
mecula, CA, USA), or by performing second SDS-
polyacrylamide gel with same probes in parallel.
Proliferation assay
Primary human meningioma cells were plated into 96-well
dishes (1,000 cells/ well), grown for two days in 20 % FCS-
supplemented DMEM, and stimulated in the same medium
with 10 nM CXCL16 (Pepro Tech), 1 μg/ml anti-CXCL16
(R&D Systems) or 10 ng/ml EGF for up to 24 h. In parallel,
control wells were kept without stimulation. Proliferation
was determined by the measurement of tetrazolium salt
WST-1 cleavage (Roche, Mannheim, Germany) and nor-
malized to non-stimulated control (4 individual wells for
each stimulus).
Caspase-3 activity assay
Primary human meningioma cells were plated into
96-well dishes (10,000 cells/ well), grown for two days
in 20 % FCS-supplemented DMEM, washed in 37 °C-
thermostatted 0.5 % FCS-supplemented DMEM for three
times (20 min, respectively), and stimulated in the same
medium with 50 μg/ml camptothecin (Sigma Aldrich,
Steinheim, Germany), 10 nM CXCL16 (Pepro Tech) or
with combination of both for up to 24 h. In parallel,
control wells without/with stimulation in DMSO were
used. For detection of active caspase-3 amounts, samples
were washed in PBS and incubated in 100 μl Homoge-
neous Caspase 3/7 substrate (Apo-ONE® Homogeneous
Caspase-3/7 Assay; Promega, Madison, USA) for 30 min
according to the manufacturer’s instruction and as de-
scribed before [15]. The amounts of active caspase-3 were
determined in relation to a caspase 7 standard (Enzo Life
Science, Lörrach, Germany), and camptothecin-stimulated
wells were set 100 %.
RNAi silencing
After cultivation of primary human meningioma cells
in DMEM plus 20 % FCS in 6-well dishes (150,000
cells/well; for Western Blot experiments) or on sterile
glass cover slides (15,000 cells/well; for binding exper-
iments) for 24 h, cells were transfected with siCXCL16
RNA (CXCL16 siRNA ID: s33808; 50 pmol/well; Life
Technologies, Darmstadt, Germany) dissolved in a
mixture of Opti-MEM Medium and lipofectamine
(Life technologies) for 6 h. In parallel a transfection
with silencer select negative control siRNA (Life
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technologies) was performed under same conditions.
After transfection cell culture medium was changed
and meningioma cells were cultured for another 24 h
in DMEM plus 20 % FCS. Then, cells were washed
20 min for three times, respectively, with DMEM plus
0.5 % FCS and afterwards stimulated for 15 min with
or without recombinant CXCL16 (10 nM; PeproTech)
dissolved in DMEM plus 0.5 % FCS, lysed and applied
for Western Blot experiments as described above. For
binding experiments primary human meningioma cells
were washed with PBS for three times, incubated for
15 min on ice, and stained with Cy3-labeled CXCL16
(2 μl diluted in 50 μl PBS) or Cy3-labeled lactalbumin
(2 μl diluted in 50 μl PBS) for 60 min on ice. Fixation
of cells and counterstaining of nuclei were performed
as described above.
For controlling the knockdown efficiency, RNA of
transfected cells were purified in parallel with the Pico-
Pure RNA Isolation Kit (MDS Analytical Technologies,
Sunnyvale, CA) according to the manufacturer’s instruc-
tions, and qRT-PCR using TaqMan primer probes (Applied
Biosystems): hGAPDH (Hs99999905_m1) and hCXCL16
(Hs00222859_m1) was performed as described above.
Results
Cultured human meningioma cells express CXCL16, but
not CXCR6
We initially measured CXCL16 and CXCR6 mRNA
(Fig. 1a) expression in cultured meningioma cells used
in our experimental settings. In comparison to CXCL16,
which was clearly detectable in all investigated samples,
CXCR6 transcription was (nearly) undetectable. To
precisely identify the primary cultures as meningioma
cells, each culture was routinely immunostained for
epithelial membrane antigen (EMA), fibronectin and
glial fibrillary acidic protein (GFAP). Examples of this
routine staining are shown in Fig. 1b. Only cultures
showing positive immunostaining for EMA and fibro-
nectin combined with negative staining for GFAP were
used for experiments. On protein level, we could detect
CXCL16 expression by immunocytochemistry and
western blots of meningioma cell membrane prepara-
tions (Fig. 1c) yielding specific bands for the trans-
membrane (tm-)CXCL16. In contrast, CXCR6 could
not be detected on protein level by western blot and
immunocytochemistry (Fig. 1d and e), and its expres-
sion was neither provoked by stimulation with 10 nM
CXCL16 nor by cultivation of different cell densities
ranging from 16,000 to 160,000 cells per well, which
represent the cell densities seeded for subsequent ex-
periments (Fig. 1e). Thus, we concluded that human
meningioma cells cultivated from different patients
samples substantially express CXCL16 expression while
CXCR6 is absent.
Cultured primary human meningioma cells bind s-CXCL16
and show subsequently activated intracellular signaling
kinases
We measured in a next step if cultured CXCR6-
negative human primary meningioma cells were able to
bind s-CXCL16 and transduce signaling effects. In fact,
Cy3-labeled s-CXCL16 was found to bind to the men-
ingioma cells (Fig. 2a), whereas Cy3-labeled lactalbu-
min as a negative control did not yield any staining.
Next to binding, s-CXCL16 was able to induce phos-
phorylation and thereby activation of both p42/44
extracellular mitogen-activated kinase (ERK1/2) and
Akt in a time-dependent manner (Fig. 2b; exemplary
results are shown). In all independent experiments, we
observed an activation of the respective kinases be-
tween 10 and 40 min. However, since primary cultures
were obtained from various patients, the time course
and intensity of activation differed between cultures.
Stimulation with epidermal growth factor (EGF) served
as a positive control.
Additionally, in accordance with our recent findings in
gliomas [10], application of a specific CXCL16 antibody
(αCXCL16) which may also induce the intrinsic activity
of tm-CXCL16, resulted in phosphorylation of both Akt
and ERK1/2 (Fig. 2b, right side) after 20 min.
Soluble s-CXCL16 induces proliferation and rescue from
apoptosis
To understand which biological consequences were in-
duced after s-CXCL16 induced “inverse signaling”, we
investigated proliferation effects and whether s-CXCL16
could prevent apoptosis in CXCR6-negative but tm-
CXCL16-positive cultured primary human meningioma
cells (Fig. 3).
Indeed, after 24 h stimulation time with s-CXCL16,
proliferation was induced up to 117 % (P1 and P3; con-
trol = 100 %) and 118 % (P4; control = 100 %; Fig. 3a).
Comparable results were detectable after application of
the specific CXCL16 antibody (αCXCL16). Valuating
these results, one should keep in mind that cultured hu-
man meningioma cells are large and slow-growing cells.
Thus, regarding the fact that the positive control yielded
proliferation of meningioma cells within the same range
(P1 = 130 %; P3 = 132 %; P4 = 126 %; control = 100 %),
CXCL16 stimulation clearly yielded proliferative effects
in these cells.
Additionally, CXCL16 was able to reduce caspase-3
activity after camptothecin treatment in CXCR6-negative
but tm-CXCL16-positive cultured primary human
meningioma cells (Fig. 3b). In detail, for sample P6
camptothecin-induced caspase-3 activity (DMSO as
control = 0 %; camptothecin dissolved in DMSO =
100 %) was reduced up to 51 %, for P7 up to 65 %, and
for P8 up to 84 % after s-CXCL16 application.
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Fig. 1 (See legend on next page.)
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CXCL16 knockdown showed specificity of results
In a next step, we aimed to show that tm-CXCL16
expression is mandatory to the signaling mediated by
s-CXCL16, to further support the hypothesis of “in-
verse signaling” in human meningioma cells. In our
recent investigations in cultured human glioma cells
we proved the specificity of this effect by several differ-
ent approaches [10]. Due to limited material and char-
acteristics of cultured meningioma cells (e.g. decreased
proliferation and increased susceptibility to apoptosis
after transfection) we chose binding experiments and
kinase activation as model experiments to prove the
specificity of the results by CXCL16 knockdown.
Results are shown in Fig. 4.
Binding of Cy3-labeled s-CXCL16 to tm-CXCL16
expressed by cultured human meningioma cells was
almost completely abolished after siCXCL16 knockdown
in the tumor cells (Fig. 4a, upper part). In contrast,
control siRNA transfected meningioma cells were still
able to bind s-CXCL16. Cy3-labeled lactalbumin served
as a negative control for testing unspecific binding
background. The expression of CXCL16 as determined
by qRT-PCR was reduced to 6.7 % (P15) and to 46 %
(P16; Fig. 4b).
Additionally, in relation to meningioma cells trans-
fected with control siRNA, siCXCL16 transfected ones
showed reduced phosphorylation and thereby activation
of ERK1/2 after s-CXCL16 treatment (exemplary results
in Fig. 4a, lower part). These results are sustained by the
reduction of CXCL16 mRNA expression to 11.5 % (P9)
and 28.7 % (P10; Fig. 4b, bottom; control siRNA = 100 %)
as determined by qRT-PCR.
Summarized, in cultured primary human meningioma
cells the classical CXCL16 receptor CXCR6 is lost, but
nevertheless CXCL16 is still able to bind to and trans-
duce signals into the cells resulting in increased prolifer-
ation and rescue of apoptosis of the cells. The binding
and subsequent cellular activation clearly depends on
the expression of tm-CXCL16 as shown by siRNA
knockdown. Thus, “inverse signaling” of the transmem-
brane chemokine CXCL16 occurs in cultured primary
human meningioma cells, and is involved in progression
of human meningiomas.
(See figure on previous page.)
Fig. 1 Expression of CXCL16 and its receptor CXCR6 in cells cultivated from human meningiomas. a Transcription of CXCL16 and its receptor
CXCR6 in human meningioma primary cultures was determined by qRT-PCR (each triangle indicates an individual patient’s sample). Meningioma
primary cultures show high mRNA levels of CXCL16, whereas the expression of CXCR6 is hardly detectable or completely lost. b The identity and
purity of meningioma cultures was assured for every culture by immunocytochemistry on EMA, fibronectin and GFAP, only cultures with positive
reactivity for EMA and fibronectin and negative staining for GFAP were used for further experiments (exemplary data). c Expression of surface
tm-CXCL16 on protein level was confirmed by immunocytochemistry using a CXCL16 specific antibody and a red labeled secondary antibody,
nuclei were counterstained with DAPI. Furthermore, membrane expression of CXCL16 was proven by western blot using membrane preparations
isolated from meningioma cells. Caveolin-1 (Cav-1) served as membrane-specific loading control. d Lack of CXCR6 expression was confirmed on
protein level by western blot. In parallel to subsequent experiments, cell lysates were analyzed using a CXCR6-specific antibody. Whereas the
positive control, human recombinant CXCR6, was sensitively detected (50 ng/lane), cultured meningioma cells did not show any CXCR6
expression. e CXCR6 expression was neither induced by CXCL16 stimulation nor by different cell densities. Stimulation with 10 nM
recombinant human CXCL16 for 24 h, the maximum stimulation time for subsequent experiments, did not yield an induction of CXCR6
expression as shown by ICC and western blot. Additionally, different cell densities in a range from 16,000 to 160,000 cell/well (representing
the cell densities seeded for subsequent experiments) did not influence on the expression of CXCR6 as shown by ICC. Exemplary data of
technical (P3 a and b different cultivation passages) and biological replicates are shown. LOX melanoma cells which were transfected with an
expression vector for human CXCR6 served as a positive control to confirm the specificity of the CXCR6 antibody in ICC, recombinant human
CXCR6 served as positive control for western blot experiments
Fig. 2 CXCL16 binds to meningioma cells and activates intracellular
signaling pathways. a Cy3-labeled s-CXCL16 binds to primary human
meningioma cells, while after incubation with Cy3-labeled lactalbumin
binding could not be observed (equal exposure times, representative
examples). b Stimulation of cultured primary meningioma cells with
10 nM s-CXCL16 (left) yields a time-dependent activation of the signal
kinases ERK1/2 and Akt as detected by western blot using antibodies
for the phosphorylated kinases (pAkt and pERK). Equal protein loading
was confirmed by detection of the non-phosphorylated kinases (Akt
and ERK2), respectively. This effect was also observed when a CXCL16-
targeting antibody (right, αCXCL16, 1 μg/ml) was used for stimulations.
EGF served as positive control, shown are representative examples of
at least 3 independent experiments with cultures from different donors
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Discussion
We recently discovered in highly malignant glioma cells
a novel form of para- or autocrine signaling mechanism
for transmembrane chemokines which we termed “in-
verse signaling” [10]. This new signaling concept antici-
pates that the proteolytically released chemokine domain
(s-chemokine) specifically binds to its transmembrane
counterpart resulting in activation of intracellular ki-
nases and induction of proliferation and anti-apoptosis.
Thus, in this novel signaling concept, the transmem-
brane ligands act as receptors for their soluble counter-
parts. This signaling concept war sustained by various
silencing and transfection experiments. It requires di-/
multimerization of the tm-chemokine, which can also be
induced by di-, but not by monovalent (Fab-fragments)
antibodies. We could also show that the intracellular do-
main (that contains motifs for binding adapter proteins)
is essential for signaling. In the present investigation we
now describe that cultured primary human meningioma
cells exhibited high CXCL16 expression in vitro, whereas
the CXCL16-specific chemokine receptor CXCR6 was
mostly absent. Facing the discrepancy between tm-che-
mokine expression and the lack of the corresponding
receptor also in meningioma cells, we hypothesized
that the concept of inverse signaling as a broad bio-
logical concept may be extended further to more benign
tumor entities.
The expression of the chemokine CXCL16 has been
reported previously for monocytes/macrophages, B
cells, dendritic cells, keratinocytes and endothelial
cells [1, 5, 19, 20] while the receptor CXCR6 has
been detected quite selectively on activated T cells,
NK cells and bone marrow plasma cells [2, 20, 21].
Apart from its physiological expression, CXCL16 is
pathologically expressed in cancer cells of different
origin including malignant glioma cells and reactive
astrocytes in situ and in vitro [5–7, 11, 22].
However, although cultured human meningioma cells
lack the CXCL16-specific receptor CXCR6, stimulation
with s-CXCL16 was able to transduce intracellular sig-
naling effects. The recombinant s-CXCL16 was able to
bind to the cell surface and to induce phosphorylation
and thereby activation of the kinases ERK and Akt in a
time dependent manner. These results are in a way com-
parable with previous ones which described CXCL16-
mediated ERK activation in schwannoma cells [6, 23], or
Akt activation in human aortic smooth muscle cells [24].
However, as the human cultured meningioma cells lack
the corresponding receptor CXCR6, a classical receptor
mediated signaling could be excluded. To investigate the
relevance of tm-CXCL16 in the observed signaling
process, we performed siCXCL16 knockdown experi-
ments and were able to show that binding to and induc-
tion of intracellular signals clearly depends on the
expression of tm-CXCL16.
In general, the activation of the ERK signal transduction
pathway often results in elevated cell growth, and the Akt
pathway in anti-apoptotic mechanisms of tumor cells.
Therefore, we wanted to know whether stimulation with
s-CXCL16 could induce these biological responses in cul-
tured primary human meningioma cells. In fact, we could
show that both effects – activation of proliferation and
rescue of apoptosis – were triggered by s-CXCL16 in cul-
tured CXCR6-negative, but tm-CXCL16-positive meningi-
oma cells. Additionally, for a more general view on the
biological role and regulation of the “inverse signaling” of
CXCL16 one should keep in mind that tm-chemokines
Fig. 3 s-CXCL16-mediated effects on proliferation and rescue from
apoptosis. a 10 nM s-CXCL16 and 1 μg/ml αCXCL16 promote the
proliferation of slowly growing human meningioma cells as measured
by MTT activity assay. EGF (10 ng/ml) served as positive control.
Control values were set 100 %, and shown are three independent
experiments with cultures from different donors, with mean ± SD
from 4 technical replicates. b When apoptosis was induced in
human primary meningioma cells by 50 μg/ml camptothecin
(Campto = 100 %), additional incubation with 10 nM CXCL16
could drastically reduce the caspase-3 activity. Shown are three
independent experiments with cultures from different donors
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like CXCL16 need to be cleaved by the cell surface
proteases ADAM10 and ADAM17 in order to pro-
duce their soluble counterparts [5]. Regarding the
biological role of CXCL16 in tumors, contrasting its
already mentioned effects in glioma and schwannoma
cells [5, 6, 21], high CXCL16 expression correlates
with good prognosis and increased levels of tumor-
infiltrating lymphocytes in renal cancer [25], while in
human rectal cancer a downregulation of CXCL16 has
been reported [26]. However, pro-tumorigenic effects of
CXCL16 have been reported for several other tumors, e.g.
breast cancer [9, 27], lung cancer, and is discussed as a
promotor of inflammation-associated cancer in general
[28], which is underlined by our own findings, that
microglia/macrophages isolated from human glioma sam-
ples show high expression levels of CXCL16 themselves
[29]. Thus, the inverse signaling mechanism of CXCL16
we here describe for meningiomas may occur in a variety
of benign and malignant tumors, modulating amongst
others the interplay between tumor and immune cells and
influencing on tumor progression. Targeting the tumor
promoting effects of CXCL16 might be a promising ther-
apy amendment e.g. for atypic meningiomas and other tu-
mors with limited treatment options.
Conclusion
Summarized, in the present investigations we were able
to show that “inverse signaling” takes place in cultured
Fig. 4 Binding of s-CXCL16 and signaling upon stimulation with s-CXCL16 depends on the tm-CXCL16 level. Expression of the tm-CXCL16 was
reduced in human meningioma cells by siRNA targeting CXCL16 (for controls, an unspecific control siRNA was used). a Knockdown of CXCL16
yielded a drastically reduced binding signal of Cy3-labeled s-CXCL16 (upper part). Additionally, we observed reduced activation of the ERK signaling
pathway as determined by Western blot on kinase phosphorylation (lower part). b The efficient knockdown of CXCL16 was determined by qRT-PCR
(bottom right). Shown are 2 independent experiments with meningioma primary cultures from different donors
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primary human meningioma cells resulting in increased
proliferation and rescue of apoptosis of these cells.
Thereby, we verified this new mechanism beside its ap-
pearance in malignant glioma cells [10] in a different
system, and showed that “inverse signaling” seems to be
a broad biological process as it is also observable in
more benign tumor cells.
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